Coagulation Market 2024 – Market Size & Segments Analysis, Industry Trends, Manufacturers Analysis, Opportunities and Forecast 2030
Page: 215 | Report Code: LS24011501 | Research Suite: Report (PDF) & Market Data (Excel)
The global market value of the coagulation market was USD 3.4 billion in 2022, and a CAGR of 5.8% is expected during the forecast period. The increasing prevalence of cardiovascular diseases and blood disorders is driving the growth of the market significantly. The rising geriatric population and the coagulation market primarily involve diagnostic and therapeutic products related to blood clotting disorders. It includes items like coagulation analyzers, reagents, and anticoagulation drugs. Increasing awareness about early diagnosis of chronic diseases and increasing patients with blood clotting disorders, along with advances in technology with effective and efficient diagnostic tools, are driving the growth of the market.
Impact of
Covid-19
The COVID-19 pandemic has had a notable impact on the
coagulation market. Increasing awareness of thrombotic events associated with
severe COVID-19 cases. This has led to a heightened focus on coagulation tests
and anticoagulant therapies. Disruptions in healthcare services and supply
chains during the pandemic have influenced market dynamics. The shift in
priorities of people focusing only on essential things is driving the growth of
the market significantly. The demand for coagulation tests increased as they
were used as markers for assessing the severity of COVID-19-induced
coagulopathy. Shift towards home-based testing solutions, emphasizing the need
for remote monitoring and patient-centric approaches in managing coagulation
disorders.
Growth Drivers
The increasing incidence of bleeding disorders, such as hemophilia and von Willebrand disease, drives the demand for coagulation products and treatments. The increasing geriatric population in most parts of the world is driving the growth of the market. Surgeries and cardiovascular diseases are required to treat these diseases. Ongoing advancements in diagnostic technologies and treatment methods contribute to the development of more efficient and targeted coagulation therapies, fostering market growth. The growing number of surgeries, including major procedures and trauma cases, boosts the demand for coagulation products to manage bleeding risks during and after this invention.
Increasing awareness about coagulation disorders, coupled with improved diagnostic capabilities, results in early detection and treatment, driving the growth of the market. Companies investing in research and development to develop novel coagulation products, therapies, and diagnostics contribute to market expansion. Higher healthcare spending globally, especially in emerging economies, supports the adoption of advanced coagulation treatments and diagnostics. Collaboration between pharmaceutical companies, research institutions, and healthcare organizations facilitates the development and commercialization of new coagulation products.
Segmentation
Product Type
·
Coagulation
Analyzers
·
Coagulation
Reagents
·
Anticoagulant
Drugs
Testing Method
·
Routine Testing
·
Specialized
Testing
End-User
·
Hospitals and
Clinics
·
Diagnostic
Laboratories
·
Research Institutes
Application
·
Hemophilia
·
Cardiovascular
Diseases
Regional
Outlook
·
Asia Pacific
·
North America
·
Europe
·
Latin America
·
Middle East and
Africa
Coagulation
Market Testing Method
On the basis of testing methods, the coagulation market
is segmented into routine testing and specialized testing. Routine testing in
the coagulation market typically involves assessing blood clotting factors,
platelet function, and overall hemostasis. Common tests include PT, APTT, and
INR. These tests include diagnosis and monitoring of conditions such as
bleeding disorders or clotting abnormalities. Advancements in coagulation
testing aim to provide more quick results. Specialized testing involves a more
detailed assessment of specific conditions. Tests like fibrinogen, D-dimer, and
factor assays target specific clotting factors.
Coagulation
Market End-User Segmentation
On the basis of end-users, the coagulation market is
segmented into hospitals, clinics, diagnostic laboratories, and research
institutes. Diagnostic laboratories are the leading segment due to the large
number of coagulation tests performed in laboratories. Hospitals are a leading
segment in the coagulation market, relying on coagulation testing to assess
patients’ blood clotting abilities. These tests help in identifying bleeding
disorders or clotting abnormalities. Hospitals use coagulation products and
equipment to ensure accurate and timely results. Aiding in the effective
management of patients with hematological issues. The coagulation market serves
hospitals by providing tools for diagnosis, treatment monitoring, and overall
patient care in the context of blood clotting disorders.
Regional
Outlook
On the basis of the regions, the coagulation market is segmented into Asia Pacific, North America, Latin America, Europe, and the Middle East and Africa. The rising number of general surgeries and increasing government initiatives are driving the growth of the Asia-Pacific market. The increasing population and growing number of accidents are also driving the growth in the market. China, India, and Japan are the biggest markets in the region. Growing research activities and a rapidly growing geriatric population are the key factors behind the growth of the market in this region.
North America, particularly the United States, has a significant share of the global coagulation market. The increasing incidence of bleeding disorders and a rise in surgical procedures are driving the growth of the market. The region benefits from advanced healthcare technologies and a strong emphasis on research and development. It contributes to the adoption of innovative coagulation products and diagnostics. The United States in particular has high healthcare expenditures, leading to increased investment in advanced medical technologies. Major global key players in the market like Siemens, Roche, and Abbott are driving the demand for growth in the Coagulation market.
Increasing awareness about the coagulation disorder and improvements in diagnostic capabilities contribute to early detection and intervention, driving the growth of the market. Demand for the coagulation products is high in hospitals, clinics, and laboratories across North America, reflecting the need for effective management of bleeding disorders. European regions, including countries like Russia, France, Spain, England, and Sweden, face a notable burden of bleeding disorders and cardiovascular diseases, contributing to the demand for coagulation products and diagnostics.
European countries generally have well-developed healthcare markets, fostering the adoption of coagulation markets. Major global players in the coagulation market, such as Roche, Siemens Healthineers, and others, have a significant presence in Europe. European countries prioritize research and development in healthcare, leading to coagulation management and diagnosis. Collaboration between research institutions, healthcare organizations, and industry players is common in Europe, fostering innovation and the development of new coagulation products.
Key Players
·
Siemens
Healthineers AG
·
F. Hoffman La
Roche Limited
·
Abbott
Laboratories
·
Sysmex
Corporation
·
Instrumentation
Laboratories
·
Nihon Kohden
Corporation
·
Thermo Fisher
Scientific
·
Horiba
·
Meril Life
Sciences
·
Erba
Diagnostics
·
Beijing
Succeeder Technology INC
·
Danaher
·
Hycil
·
Werfen Company
·
Bio-Rad
Laboratories
· Other Players